• Publications
  • Influence
Cellular imaging predictions of clinical drug-induced liver injury.
Drug-induced liver injury (DILI) is the most common adverse event causing drug nonapprovals and drug withdrawals. Using drugs as test agents and measuring a panel of cellular phenotypes that areExpand
  • 362
  • 30
Applying computational modeling to drug discovery and development.
Computational models of cells, tissues and organisms are necessary for increased understanding of biological systems. In particular, modeling approaches will be crucial for moving biology from aExpand
  • 116
  • 2
A network-based approach to quantifying the impact of biologically active substances.
Fe at u re s P E R S P E C T IV E Society increasingly demands close scrutiny of the potential health risks of long-term exposure to biologically active substances, such as therapeutic drugs orExpand
  • 83
  • 1
Early patient stratification and predictive biomarkers in drug discovery and development: a case study of ulcerative colitis anti-TNF therapy.
The current drug discovery paradigm is long, costly, and prone to failure. For projects in early development, lack of efficacy in Phase II is a major contributor to the overall failure rate. EfficacyExpand
  • 16
Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis
BackgroundFaced with an increasing number of choices for biologic therapies, rheumatologists have a critical need for better tools to inform rheumatoid arthritis (RA) disease management. The abilityExpand
  • 19
Systems diagnostics: anticipating the next generation of diagnostic tests based on mechanistic insight into disease.
Societal demand for faster and more accurate assignment of treatments is based in both patient care needs and in health economics. From a patient care standpoint, there needs to be a transformationExpand
  • 18
Isolation of altered-function mutants and genetic suppressor elements of multidrug transporter P-glycoprotein by expression selection from retroviral libraries.
Publisher Summary This chapter describes the expression–selection procedures to identify the amino acid residues and protein domains responsible for different intra- and intermolecular interactionsExpand
  • 4
A decade of Systems Biology: where are we and where are we going to?
1359-6446/06/$ see front matter 2013 Published by Elsevier Ltd. http://dx.doi.org/10.1016/j.drudis.2013. integrated into many research organizations. Its emergence is largely the result of theExpand
  • 5
Multi-omic biomarkers unlock the potential of diagnostic testing.
  • 1
Company Profile: Selventa, Inc.
Selventa, Inc. (MA, USA) is a biomarker discovery company that enables personalized healthcare. Originally founded as Genstruct, Inc., Selventa has undergone significant evolution from aExpand